CAR-T Therapy Shows Safety and Effectiveness in Cancer Patients with Autoimmune or Inflammatory Diseases

In a groundbreaking study recently published in The Lancet Rheumatology, researchers from Dana-Farber Cancer Institute have evaluated the safety and efficacy of CAR-T cell therapy in cancer patients with a history of autoimmune or inflammatory diseases. The study, which reviewed data from 2017 to 2023, included 604 patients with lymphoma and Multiple Myeloma, of whom 53 had underlying autoimmune or inflammatory conditions. These conditions included rheumatoid diseases, with psoriasis being the most common.

CAR-T cell therapy, specifically targeting CD19 and BCMA, has shown remarkable success in treating relapsed and refractory B-Cell Lymphoma, leukemia, and multiple myeloma. However, concerns have arisen regarding its safety and efficacy in patients with pre-existing autoimmune or inflammatory diseases, as these patients are at higher risk for severe reactions like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

The study found that the incidence of CRS and ICANS in patients with autoimmune or inflammatory diseases was similar to that of patients without these conditions. Specifically, the rates of severe CRS were minimal, with no significant difference between the two groups. The occurrence of ICANS was also comparable, suggesting that CAR-T therapy is safe for these patients.

In terms of efficacy, there was no significant difference in progression-free survival (PFS) and overall survival (OS) between the two groups, further confirming that the presence of autoimmune or inflammatory diseases does not adversely affect the Cancer Treatment outcomes. Interestingly, the study also observed improvements in autoimmune disease activity post-treatment. A significant reduction in the need for immunosuppressants was seen, and disease flare-ups were less frequent in the treatment group.

This study provides robust evidence supporting the use of CAR-T therapy in patients with concurrent autoimmune or inflammatory diseases, indicating that it is a viable option for a broader range of cancer patients. The findings encourage further prospective studies to explore the potential benefits of CAR-T therapy in this unique patient population.

As CAR-T therapies continue to evolve, these results offer hope for improving treatment options and outcomes for patients with complex medical histories.